10-KPeriod: FY2010

QUEST DIAGNOSTICS INC Annual Report, Year Ended Dec 31, 2010

Filed February 16, 2011For Securities:DGX

Summary

Quest Diagnostics, a leader in diagnostic testing, reported $7.4 billion in net revenues for the fiscal year ended December 31, 2010. The company's strategy focuses on leveraging its extensive assets, driving medical innovation, delivering a superior patient experience, and maintaining high quality through Six Sigma processes. Significant investments in healthcare information technology, such as the Care360 suite, are aimed at improving patient care and clinician workflow, with the Care360 EHR solution receiving ONC-ATCB certification. The company operates in a competitive market influenced by healthcare reform, demographic trends, and technological advancements. Quest Diagnostics' diverse revenue streams include clinical testing (91% of 2010 revenues), life insurer services, clinical trials testing, diagnostic products, and employer services. Despite a slight decrease in net revenues compared to 2009, the company managed its costs effectively, resulting in stable operating income as a percentage of revenue, supported by reduced bad debt expenses and operational efficiencies.

Financial Statements
Beta
Revenue$7.26B
Cost of Revenue$4.28B
Gross Profit$3.05B
SG&A Expenses$1.66B
Operating Expenses$5.98B
Operating Income$1.28B
Interest Expense$147.50M
Net Income$720.89M
EPS (Basic)$4.08
EPS (Diluted)$4.05
Shares Outstanding (Basic)175.68M
Shares Outstanding (Diluted)177.32M

Key Highlights

  • 1Quest Diagnostics generated $7.4 billion in net revenues for the fiscal year ended December 31, 2010.
  • 2The company's strategy emphasizes leveraging its broad assets, medical innovation, superior patient experience, and Six Sigma quality.
  • 3Clinical testing accounted for the vast majority of revenue (91%), with other segments including life insurer services, clinical trials, and diagnostics products.
  • 4Investments in healthcare IT, notably the Care360 suite, are highlighted as a differentiator, supporting electronic health records and physician workflow.
  • 5The company experienced a slight revenue decline of 1.2% compared to the prior year, primarily due to lower clinical testing volumes.
  • 6Operating income remained strong as a percentage of revenue, supported by cost management initiatives, including reduced bad debt expenses.
  • 7Quest Diagnostics continues to operate in a dynamic healthcare landscape influenced by regulatory changes, competition, and technological advancements.

Frequently Asked Questions

In 2010, Quest Diagnostics derived the vast majority of its revenue (91%) from its clinical testing business. Other significant revenue streams included life insurer services, clinical trials testing, healthcare information technology, and diagnostic products.

Quest Diagnostics acknowledged the significant impact of U.S. healthcare reform legislation. While expecting expanded coverage to benefit industry utilization, the company noted potential offsets from cost-reduction provisions impacting Medicare fee schedules. They expressed confidence in their ability to adapt to these evolving market forces.

Quest Diagnostics' strategy is multifaceted, focusing on leveraging its extensive network and capabilities, leading in medical innovation and IT solutions, delivering a superior patient experience, and continuously driving quality through Six Sigma processes. The company also aims to expand its geographic reach and its portfolio in point-of-care testing.

The filing mentions ongoing legal proceedings, including investigations related to billing practices with MediCal (California Medicaid) and a federal False Claims Act complaint. While the company believes it is in compliance, it has engaged in discussions and settled some matters, indicating a continued focus on compliance and risk management.